|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, December 10, 2016 ) Asthma is a chronic disease involving the airways in the lungs. These airways, or bronchial tubes, allow air to come in and out of the lungs. Symptoms include shortness of breath, chest tightness or pain, chronic coughing and trouble sleeping due to coughing or wheezing. The predisposing factors include family history, overweight, smoking, exposure to exhaust fumes or other types of pollution and exposure to occupational triggers, such as chemicals used in farming, hairdressing and manufacturing. Treatment includes inhaled corticosteroids, leukotriene modifiers, antihistamines and decongestants.
Report Highlights :
Publisher's Pharmaceutical and Healthcare latest pipeline guide Asthma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Asthma (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Asthma (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Asthma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 6, 16, 44, 36, 124, 25 and 2 respectively for Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 24 and 8 molecules, respectively for Asthma.
Asthma (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
For more information about this report at http://www.reportsweb.com/asthma-pipeline-review-h2-2016
Report Scope:
- The pipeline guide provides a snapshot of the global therapeutic landscape of Asthma (Respiratory).
- The pipeline guide reviews pipeline therapeutics for Asthma (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Asthma (Respiratory) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Asthma (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Asthma (Respiratory)
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001453559/sample
Reasons to buy:
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Asthma (Respiratory).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Asthma (Respiratory) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Companies profiles
4D Pharma Plc
AB Science SA
AbbVie Inc
Abeome Corporation
Accolade Pharmaceuticals, LLC
Acorda Therapeutics, Inc.
Adamis Pharmaceuticals Corporation
Advinus Therapeutics Ltd
Afferent Pharmaceuticals, Inc.
ALK-Abello A/S
Allergopharma GmbH & Co. KG
Almirall, S.A.
Amakem NV
Amgen Inc.
AnaptysBio, Inc.
AnGes MG, Inc.
Antisense Therapeutics Limited
ARA Healthcare Pvt. Ltd.
Array BioPharma Inc.
ASIT biotech s.a.
Astellas Pharma Inc.
AstraZeneca Plc
Asubio Pharma Co., Ltd.
Aurigene Discovery Technologies Limited
Axikin Pharmaceuticals, Inc.
Bioncotech Therapeutics SL
Biotec Pharmacon ASA
Boehringer Ingelheim GmbH
CalciMedica, Inc.
Cellceutix Corporation
Cellular Biomedicine Group, Inc.
Celon Pharma Sp. z o.o.
Chiesi Farmaceutici SpA
Circassia Pharmaceuticals Plc
Cognosci, Inc.
CSL Limited
Cumberland Pharmaceuticals, Inc.
Cynata Therapeutics Limited
Daiichi Sankyo Company, Limited
F. Hoffmann-La Roche Ltd.
Foresee Pharmaceuticals, LLC
Fountain Biopharma Inc.
Genentech, Inc.
GlaxoSmithKline Plc
Griffin Discoveries BV
Han Wha Pharma Co., Ltd.
HitGen LTD
Hydra Biosciences, Inc.
iCeutica, Inc.
iCo Therapeutics Inc.
Immupharma Plc
Infinity Pharmaceuticals, Inc.
INOXIA Lifesciences GmbH
Intech Biopharm Ltd
Invion Limited
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Johnson & Johnson
Kissei Pharmaceutical Co., Ltd.
Kolltan Pharmaceuticals, Inc.
KPI Therapeutics, Inc.
Kyowa Hakko Kirin Co., Ltd.
Lead Discovery Center GmbH
LegoChem Biosciences, Inc
Ligand Pharmaceuticals, Inc.
Lpath, Inc.
Mabtech Limited
Marinomed Biotechnologie GmbH
MedImmune, LLC
Merck & Co., Inc.
Mitsubishi Tanabe Pharma Corporation
Mycenax Biotech Inc.
NAL Pharmaceuticals Ltd.
NeoPharm Co., Ltd.
Novartis AG
Omeros Corporation
Ono Pharmaceutical Co., Ltd.
OPKO Health, Inc.
Orbis Biosciences Inc
Orion Oyj
Oxagen Limited
Palatin Technologies, Inc.
Panacea Biotec Limited
Panmira Pharmaceuticals, LLC.
Paradigm Biopharmaceuticals Limited
Peptinnovate Ltd
Pfizer Inc.
PharmaLundensis AB
Pharmaxis Limited
Pieris Pharmaceuticals Inc
Pila Pharma AB
Polyphor Ltd.
Promedior, Inc.
Prommune, Inc.
Protectimmun GmbH
Prous Institute for Biomedical Research S.A.
Pulmagen Therapeutics LLP
Pulmokine, Inc.
Re-Pharm Limited
Regeneron Pharmaceuticals Inc
Respiratorius AB
ReveraGen BioPharma, Inc.
Rhizen Pharmaceuticals S.A.
Saje Pharma, LLC
Shire Plc
Spring Bank Pharmaceuticals, Inc.
Stallergenes Greer plc
Sterna biologicals Gmbh & Co KG
Sumitomo Dainippon Pharma Co., Ltd.
Sun Pharma Advanced Research Company Ltd.
Sunovion Pharmaceuticals Inc.
Swecure AB
Synermore Biologics Co Ltd
Synovo GmbH
Syntrix Biosystems, Inc.
TaiwanJ Pharmaceuticals Co., Ltd.
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd.
The International Biotechnology Center (IBC) Generium
Therabron Therapeutics, Inc.
Theravance Biopharma, Inc.
Tolerys SA
United BioPharma, Inc.
Vectura Group Plc
Verona Pharma Plc
WhanIn Pharmaceutical Co., Ltd.
Xencor, Inc.
Yungjin Pharm. Co., Ltd.
Zambon Company S.p.A.
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001453559/discount
List of Figures:
Number of Products under Development for Asthma, H2 2016 41
Number of Products under Development for Asthma - Comparative Analysis, H2 2016 42
Number of Products under Development by Companies, H2 2016 43
Number of Products under Investigation by Universities/Institutes, H2 2016 55
Comparative Analysis by Late Stage Development, H2 2016 57
Comparative Analysis by Clinical Stage Development, H2 2016 58
Comparative Analysis by Early Stage Products, H2 2016 59
Assessment by Monotherapy Products, H2 2016 208
Assessment by Combination Products, H2 2016 209
Number of Products by Top 10 Targets, H2 2016 210
Number of Products by Stage and Top 10 Targets, H2 2016 210
Number of Products by Top 10 Mechanism of Actions, H2 2016 222
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 222
Number of Products by Top 10 Routes of Administration, H2 2016 241
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 241
Number of Products by Top 10 Molecule Types, H2 2016 243
Number of Products by Stage and Top 10 Molecule Types, H2 2016 243
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
